Company Expands Product Portfolio and Enters Over $10 Billion Global Market for Mind, Memory and Mood Enhancers
LAS VEGAS, NV, July 28, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – BioAdaptives Inc. (OTCMkts: BDPT) announces the launch of MindnMemory, an advanced nootropic designed to improve memory, mental focus, clarity and concentration. MindnMemory has a gradual, smooth and prolonged effect, maintaining the beneficial effects without the sudden “high” and “crash” produced by caffeine and similar substances. The company developed and trial marketed this stimulant-free formula, based on traditional Chinese medicine and Ayurvedic culture, in response to strong demand for a premium product that promotes optimal performance. MindnMemory is designed to benefit not only those with age-related cognitive decline, but also anyone, including e-Gamers, seeking maximum perception, judgment, accuracy, reaction speed, and mood elevation.
Ongoing research suggests that nootropics may also play a role in mental health. According to the World Health Organization, approximately 300 million people are affected by depression worldwide, with women being more affected than men. Nootropics may be useful as supplements to treat symptoms of dementia and minor forms of cognitive decline, anxiety disorders, and other mental symptoms.
Market research estimates that global sales of nootropics exceeded $10.5 billion USD in 2021, and that this segment of nutraceuticals is growing at a rate of up to 18% per year; Current estimates call for global sales to approach $31 billion by 2029.
Edward Jacobs, MD, CEO of BioAdaptives, states: “An all-natural supplement formula, MindnMemory promotes sustained and peak mental and physical performance.
At the cellular level, this benefit is supported by increased mitochondrial energy production, especially in the nervous, cardiovascular, and muscular systems.
Consumers, including seniors with or without cognitive impairments, as well as e-Gamers and those engaged in activities that require extended periods of attention and intense concentration, report that MindnMemory’s ingredients help them achieve clear thinking, focus, faster recall, a sense of well-being, and resistance to mental and physical fatigue. We are encouraged by the early success of MindnMemory to expand our development of more innovative formulations to further benefit mental functionality. “
About BioAdaptives, Inc.
BioAdaptives, Inc. manufactures and distributes natural plant- and algae-based products that improve the health and well-being of humans and animals, with an emphasis on optimizing pain relief, antiviral activity, and immune system defense; stress resistance; endurance; recovery from injuries, illnesses and exercise; and anti-aging properties.
The Company’s current dietary supplement formulations are carefully selected from the best sources around the world and use proprietary methods to enhance the bioavailability of nutrients. Products for horses and dogs have also been shown to increase general health, improve competitive performance, rejuvenate and relieve pain effects, as well as provide improvements in appearance. Our current product line includes PrimiLungs™ and PluriPain® for humans and Equine All-in-One™ for horses.
Additional human products, coming soon, are designed to support memory, cognition and focus; help in the reduction of sleep and fatigue; and improve overall emotional and physical well-being. BioAdaptives common shares trade on the OTC market under the symbol BDPT. It has more than 13,000 current shareholders. None of the statements about the Company’s products have been approved by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Additional information can be found at www.shopbioadaptives.com or in our filings with the SEC at https://www.sec.gov/cgi-bin/browse-edgar?company=bioadaptives&owner=exclude&action=getcompany
safe harbor statement
This news release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this news release, including words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend” and other similar expressions of opinion constitute forward-looking statements. Any forward-looking statement involves risks and uncertainties that could cause actual results to differ materially from the future results described in the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company’s reports filed with the Securities and Exchange Commission. The forward-looking information provided in this document represents the Company’s estimates as of the date ha of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company specifically disclaims any obligation to update any forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as a representation of the Company’s estimates of its future financial performance as of any date after the date of this news release.
Contact:
Investor Relations
BioAdaptives, Inc.
(702) 659-8829
[email protected]
.
